INT200185

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.26
First Reported 2006
Last Reported 2010
Negated 0
Speculated 3
Reported most in Body
Documents 10
Total Number 12
Disease Relevance 11.40
Pain Relevance 1.47

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular region (Igfals) cell adhesion (Igfals) nucleus (Igfals)
Anatomy Link Frequency
motor neurons 3
neuronal 1
liver 1
spinal cord 1
microglia 1
Igfals (Mus musculus)
Pain Link Frequency Relevance Heat
Inflammation 106 100.00 Very High Very High Very High
Spinal cord 184 98.84 Very High Very High Very High
Glutamate receptor 15 98.62 Very High Very High Very High
Glutamate 123 97.48 Very High Very High Very High
Central nervous system 36 94.52 High High
COX-2 inhibitor 20 91.08 High High
Gabapentin 40 90.48 High High
Lamotrigine 20 88.56 High High
medulla 33 75.36 Quite High
cytokine 60 54.40 Quite High
Disease Link Frequency Relevance Heat
Motor Neuron Diseases 1322 100.00 Very High Very High Very High
INFLAMMATION 126 100.00 Very High Very High Very High
Hutchinson-gilford Progeria Syndrome 41 99.64 Very High Very High Very High
Death 106 98.88 Very High Very High Very High
Targeted Disruption 191 98.24 Very High Very High Very High
Nerve Degeneration 27 94.32 High High
Disease 326 94.16 High High
Stress 89 94.12 High High
Hypoglycemia 8 92.52 High High
Parkinson's Disease 23 89.92 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Riluzole, the only effective drug in ALS, was developed without the use of the SOD1 transgenic mice model.158 Based on these observations, the utility of animal models in the preclinical phase for identifying therapeutic agents in ALS has been doubted.23,103
Regulation (effective) of ALS associated with targeted disruption and motor neuron diseases
1) Confidence 0.26 Published 2009 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2785861 Disease Relevance 0.95 Pain Relevance 0.11
The management of ALS patients is still supportive and symptoms-based and, actually, riluzole is the only compound that demonstrated a beneficial effect on ALS patients, but with only modest increase in survival.
Regulation (effect) of ALS associated with motor neuron diseases
2) Confidence 0.26 Published 2009 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2785861 Disease Relevance 1.10 Pain Relevance 0.13
Riluzole, the only effective drug in ALS, was developed without the use of the SOD1 transgenic mice model.158 Based on these observations, the utility of animal models in the preclinical phase for identifying therapeutic agents in ALS has been doubted.23,103
Regulation (Riluzole) of ALS associated with targeted disruption and motor neuron diseases
3) Confidence 0.26 Published 2009 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2785861 Disease Relevance 0.96 Pain Relevance 0.11
Clinical trials including “cocktail therapies” should also be designed using new drugs as add-on therapies to riluzole.23 Preclinical studies in SOD1 transgenic mice indicated that therapy combinations are more effective than individual agents.119,144 This approach has recently been considered in a phase II clinical trial and it appeared feasible, efficient, and has been demonstrated some beneficial effect on ALS patients.89 Furthermore, important news should be provided in the next years by research focused on drug delivery via viral vectors or compounds interfering with transcriptional dysregulation, protein aggregation, and disease-causing mutations.
Regulation (effect) of ALS associated with targeted disruption, disease and motor neuron diseases
4) Confidence 0.16 Published 2009 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2785861 Disease Relevance 0.61 Pain Relevance 0
The enzyme cyclooxygenase-2 (COX-2) has been proposed as an attractive therapeutic target in ALS because its increase in the spinal cord stimulates astrocytic glutamate release.118 Elevated levels of COX-2 and prostaglandin E2 have been observed in the spinal cord of SOD1 mutant mice and ALS patients.118 Celecoxib, a COX-2 inhibitor has been shown to be beneficial in preclinical testing, prolonging survival of SOD1 mice.119,120 A 12-month double-blind placebo-controlled clinical trial was conducted on 300 patients with ALS.
Regulation (target) of ALS in spinal cord associated with glutamate, cox-2 inhibitor, motor neuron diseases and spinal cord
5) Confidence 0.16 Published 2009 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2785861 Disease Relevance 0.76 Pain Relevance 0.24
These findings suggest that barrier permeability may be affected in ALS.
Spec (may) Regulation (affected) of ALS associated with motor neuron diseases
6) Confidence 0.12 Published 2007 Journal PLoS ONE Section Body Doc Link PMC2075163 Disease Relevance 1.36 Pain Relevance 0.22
IGF-1, ALS, and prolactin receptor are three of a surprisingly limited number of liver transcripts reported to be altered in the long-lived GHR-KO dwarf (only ten genes at a significance of p < 0.001), while in Snell dwarf mice and calorie-restricted mice, hundreds of liver transcripts are differentially expressed using the same experimental platform and statistical criteria [39].
Regulation (altered) of ALS in liver
7) Confidence 0.11 Published 2006 Journal PLoS Genetics Section Body Doc Link PMC1698946 Disease Relevance 0.28 Pain Relevance 0
To demonstrate whether BV affected neuroinflammation in a familial ALS animal model, we studied the relationship between microglia activation and inflammatory factors in symptomatic hSOD1G93A mice.
Spec (whether) Regulation (affected) of ALS in microglia associated with inflammation and motor neuron diseases
8) Confidence 0.10 Published 2010 Journal J Neuroinflammation Section Body Doc Link PMC2974667 Disease Relevance 0.56 Pain Relevance 0.31
Modulation of immune/inflammatory effectors in ALS could have a protective effect for dying motor neurons.
Regulation (Modulation) of ALS in motor neurons associated with inflammation and motor neuron diseases
9) Confidence 0.09 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2429976 Disease Relevance 0.74 Pain Relevance 0.15
The contribution of excessive Ca2+ influx through glutamate receptors to the death of motor neurons suggest that RNA editing might play a role in ALS.
Spec (might) Regulation (role) of ALS in motor neurons associated with glutamate receptor, motor neuron diseases and death
10) Confidence 0.04 Published 2009 Journal Mol Brain Section Body Doc Link PMC2694175 Disease Relevance 1.77 Pain Relevance 0.21
Now our results indicate that reduction in glycolytic energy supply is in itself a factor contributing to ALS pathology, suggesting as one overriding cause of ALS-related neuronal cell death the depletion of intracellular ATP levels by a combined reduction of the TCA cycle, oxidative phosphorylation and glycolysis.
Regulation (contributing) of ALS in neuronal associated with death and motor neuron diseases
11) Confidence 0.04 Published 2007 Journal BMC Genomics Section Body Doc Link PMC1796866 Disease Relevance 1.36 Pain Relevance 0
A depletion of microtubules and neurofilaments has deleterious effects on motoneurons, according to our present understanding of their role in ALS pathogenesis [1].
Regulation (role) of ALS in motoneurons associated with motor neuron diseases
12) Confidence 0.04 Published 2007 Journal BMC Genomics Section Body Doc Link PMC1796866 Disease Relevance 0.94 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox